| 000 | 01722 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516084124.0 | ||
| 264 | 0 | _c20120619 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a1096-8652 | ||
| 024 | 7 |
_a10.1002/ajh.23164 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHenk, Henry J | |
| 245 | 0 | 0 |
_aPersistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. _h[electronic resource] |
| 260 |
_bAmerican journal of hematology _cMay 2012 |
||
| 300 |
_a490-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Utilization |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFractures, Spontaneous _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInternational Classification of Diseases |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMedication Adherence |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xcomplications |
| 650 | 0 | 4 |
_aOsteolysis _xepidemiology |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aTeitelbaum, April | |
| 700 | 1 | _aPerez, Jose Ricardo | |
| 700 | 1 | _aKaura, Satyin | |
| 773 | 0 |
_tAmerican journal of hematology _gvol. 87 _gno. 5 _gp. 490-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ajh.23164 _zAvailable from publisher's website |
| 999 |
_c21657476 _d21657476 |
||